TLX Stock — Telix Pharmaceuticals Limited: Cash, EV, Pipeline

Share price

$12.59

Market cap

$4,265.2M

Cash

$141.9M

Enterprise value

$4,528.3M

Balance sheet

Cash	$141.9M
Debt	$405.0M
Net cash	-$263.1M
Enterprise value	$4,528.3M
Basic shares	338.9M shares
Fully diluted shares	338.3M shares
Fully diluted market cap	$4,259.6M
Cash per share	$0.42

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading TLX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 26	68Ga-PSMA-11	Phase 3	PCA; Prostate Cancer; Prostatic Neoplasm	—
Jun 7 - Jul 19	153Sm-DOTMP	Phase 1	Bone Pain; Metastatic Bone Tumor; Bone Metastases in Subjects With Advanced Cancer	—
Jul 13 - Aug 24	131I-IPA	Phase 1	Neoplastic Disease; Glioblastoma; Glioblastoma Multiforme	—
Nov 12 - Dec 24	89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)	Phase 1	Soft Tissue Sarcoma; PDGFR Alpha Positive Solid Tumours	—
Jan 12 - Feb 23	177Lu-TLX591	Phase 3	Metastatic Castration-resistant Prostate Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Illuccix

Approved · Active Modality: radiopharmaceutical (imaging)

Target PSMA

Indications

Prostate cancer imaging (Approved)

Status note Radiopharmaceutical product launched in Apr 2022. Approved by FDA, Australian TGA, Health Canada, Brazil ANVISA, UK MHRA and health regulators in 19 EEA member states.

Gozellix

Approved · Active Modality: radiopharmaceutical (imaging)

Target PSMA

Indications

Prostate cancer imaging (Approved)

Status note Radiopharmaceutical product approved by FDA in Mar 2025 and launched in Jun 2025. Indication detail not stated in the excerpts.

Pixclara

Stage not disclosed · Active Modality: radiopharmaceutical

Aliases TLX101-Px

Indications

not disclosed (Stage not disclosed)

Catalysts

— n/a

Status note Product candidate for which the company is working on an FDA resubmission. Indication and trial phase not stated in the excerpts.

Zircaix

Stage not disclosed · Active Modality: radiopharmaceutical

Aliases TLX250-Px

Target CAIX

Indications

not disclosed (Stage not disclosed)

Catalysts

— n/a

Status note Product candidate for which the company is working on an FDA resubmission. Indication and trial phase not stated in the excerpts.

Per-asset detail extracted from the 20-F filed 2026-02-20. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	68Ga-PSMA-11
Lead indication	PCA
Lead phase	Phase 3
Active trials	9
Collaborator trials	7

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07052214	Phase 3	Recruiting	Sponsor	TLX	—	PCA; Prostate Cancer; Prostatic Neoplasm	—
NCT07100730	Phase 3	Recruiting	Sponsor	TLX	—	Neoplastic Disease; Glioblastoma; Glioblastoma (GBM)	—
NCT07197580	Phase 3	Recruiting	Sponsor	TLX	—	ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC)	—
NCT06520345	Phase 3	Recruiting	Sponsor	TLX	—	Metastatic Castration-resistant Prostate Cancer	—
NCT06750419	Phase 3	Recruiting	Sponsor	TLX	—	Clear Cell Renal Cell Carcinoma	—
NCT07197645	Phase 1	Recruiting	Sponsor	TLX	—	Bone Pain; Metastatic Bone Tumor; Bone Metastases in Subjects With Advanced Cancer	—
NCT05450744	Phase 1	Active, not recruiting	Sponsor	TLX	—	Neoplastic Disease; Glioblastoma; Glioblastoma Multiforme	—
NCT06537596	Phase 1	Recruiting	Sponsor	TLX	—	Soft Tissue Sarcoma; PDGFR Alpha Positive Solid Tumours	—
NCT05868174	Phase 1	Recruiting	Sponsor	TLX	—	Solid Tumor, Adult; Advanced Solid Tumor; Advanced Renal Cell Carcinoma	—
NCT07077083	Phase 2	Not yet recruiting	Collaborator	Massachusetts General Hospital	—	Clear Cell Renal Cell Carcinoma (ccRCC); ccRCC	—
NCT05663710	Phase 2	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Advanced Cancer; Clear Cell Renal Cell Carcinoma	—
NCT04402151	Phase 2	Recruiting	Collaborator	Weill Medical College of Cornell University	—	Prostate Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 7 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 16 active trials for Telix Pharmaceuticals (Innovations) Pty Limited on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

TLX — Telix Pharmaceuticals Limited

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials